NEW YORK, Feb. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS).   Such investors are advised to contact Robert S. Willoughby at  newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Gossamer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On December 6, 2022, Gossamer issued a press release “announc[ing] topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension (PAH).”  Although the Company represented that seralutinib met the primary endpoint in the clinical trial, Wall Street analysts questioned its performance, noting that the therapy did not outperform Merck & Co. Inc’s sotatercept product. 

On this news, Gossamer’s stock price fell $6.93 per share, or 74.6%, to close at $2.36 per share on December 6, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

CONTACT: 
Robert S. Willoughby
Pomerantz LLP 
rswilloughby@pomlaw.com 
888-476-6529 ext. 7980

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.